CME Group
CME
$277.77
-3.03%
CME Group Inc. operates the world's leading derivatives marketplace, providing a diverse range of futures and options products across interest rates, equity indexes, foreign exchange, energy, agriculture, and metals. As a dominant exchange operator with a near-monopoly in U.S. listed derivatives, CME benefits from deep liquidity, network effects, and a highly scalable electronic trading platform. The current investor narrative centers on how rising interest rates and inflation are boosting trading volumes and revenue, while the company's strategic investments in technology and data services position it for long-term growth. However, concerns about regulatory scrutiny, competition from new entrants, and the cyclicality of trading activity keep the stock's valuation in check.…
CME
CME Group
$277.77
Related headlines
Investment Opinion: Should I buy CME Today?
Based on the analysis, CME is rated a 'Hold' with a thesis that the stock is fairly valued with limited upside potential. The consensus recommendation is 'Hold' with an average target price of $283.07, implying a slight downside of -0.96%. The stock offers a compelling combination of high margins, strong cash flow, and defensive characteristics, but the valuation leaves little room for error.
Sign up to view all
CME 12-Month Price Forecast
CME's fundamentals are strong, but the valuation is fair, and analyst sentiment is cautious. The stock's defensive nature and high dividend yield make it attractive for income investors, but growth prospects are limited. I would upgrade to bullish if revenue growth accelerates above 15% and the P/E compresses below 20x, or downgrade to bearish if volumes decline significantly and the stock breaks below $250.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on CME Group's 12-month outlook, with a consensus price target around $283.07 and implied upside of +1.9% versus the current price.
Average Target
$283.07
0 analysts
Implied Upside
+1.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$230 - $330
Analyst target range
CME is covered by 15 analysts, with a consensus recommendation of 'Hold' and a mean rating of 2.56 (where 1 is Strong Buy and 5 is Sell). The average target price is $283.07, implying a slight downside of -0.96% from the current price of $285.80. The target range is $230.00 to $330.00, with the low target suggesting a potential 19.5% downside and the high target a 15.5% upside. Recent ratings have been mostly positive, with upgrades from KBW and Rothschild, but the overall sentiment remains cautious, reflecting uncertainty about future trading volumes and regulatory risks.
Drowning in data?
Find the real signal!
Bulls vs Bears: CME Investment Factors
CME Group presents a compelling investment case with robust revenue growth, exceptional profitability, and strong cash generation, underpinned by a defensive business model. However, the stock's valuation is rich, and analyst targets suggest limited upside, reflecting concerns about cyclical trading volumes and regulatory risks. The bull case is supported by the company's dominant market position and ability to monetize volatility, while the bear case hinges on potential volume declines and valuation compression. The most critical tension is whether CME can sustain its revenue growth trajectory as interest rate dynamics evolve, which will determine if the current premium valuation is justified.
Bullish
- Robust Revenue Growth: Q1 2026 revenue surged 14.48% YoY to $1.88 billion, driven by strong trading volumes across all asset classes. This demonstrates the company's ability to capitalize on market volatility and interest rate fluctuations.
- Exceptional Profitability: Net margin of 61.4% and operating margin of 69.7% highlight CME's highly scalable business model with minimal incremental costs. Gross margin of 88.1% underscores the pricing power of its exchange franchise.
- Strong Cash Generation: Free cash flow for the trailing twelve months reached $4.33 billion, providing ample capacity for dividends and share buybacks. This supports a dividend yield of 4.0%, attractive for income-focused investors.
- Defensive Characteristics: With a beta of 0.267, CME is significantly less volatile than the broader market, making it a defensive holding during economic uncertainty. Its diversified product suite across rates, equities, and commodities provides stability.
Bearish
- Limited Analyst Upside: The average analyst target price of $283.07 implies a slight downside of -0.96% from the current price of $285.80. With a consensus 'Hold' rating, analysts see limited near-term appreciation potential.
- Cyclical Trading Volumes: Revenue is highly dependent on market volatility and trading activity, which can decline during calm periods. The 6-month price change of -10.55% reflects a significant drawdown, highlighting sensitivity to market conditions.
- High Valuation Multiple: Trailing P/E of 24.43x and forward P/E of 22.10x are above the broader market, leaving little room for multiple expansion. If growth decelerates, the stock could face de-rating risk.
- Regulatory and Competitive Pressures: Potential regulatory scrutiny and competition from new entrants could erode market share. The company's near-monopoly status may attract antitrust attention, while emerging exchanges pose long-term threats.
CME Technical Analysis
CME's stock has exhibited a volatile, range-bound pattern over the past year, currently trading at $285.80, up 7.13% from a year ago. The price sits at 86.8% of its 52-week range (low of $218.31, high of $329.16), indicating a recovery from the June lows but still below the highs. The 6-month change of -10.55% reflects a significant drawdown, yet the 1-year positive return suggests resilience. The stock's beta of 0.267 indicates it is significantly less volatile than the market, making it a defensive holding in turbulent times.
Beta
0.27
0.27x market volatility
Max Drawdown
-33.0%
Largest decline past year
52-Week Range
$218-$329
Price range past year
Annual Return
+4.7%
Cumulative gain past year
| Period | CME Return | S&P 500 |
|---|---|---|
| 1m | +4.4% | +1.0% |
| 3m | +8.5% | +1.1% |
| 6m | -12.4% | +13.8% |
| 1y | +4.7% | +19.5% |
| ytd | +3.0% | +12.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CME Fundamental Analysis
CME's revenue growth has been robust, with Q1 2026 revenue of $1.88 billion, up 14.48% year-over-year, driven by strong trading volumes across all asset classes. The company's net income for Q1 2026 was $1.15 billion, with a net margin of 61.4%, reflecting its highly profitable business model. Gross margin stood at 88.1%, and operating margin at 69.7%, both indicating exceptional operational efficiency. The company's balance sheet is solid, with a debt-to-equity ratio of 0.13 and a current ratio of 92.97, ensuring ample liquidity. Free cash flow for the trailing twelve months was $4.33 billion, providing strong cash generation to support dividends and share buybacks.
Quarterly Revenue
$1.9B
2026-03
Revenue YoY Growth
+14.5%
YoY Comparison
Gross Margin
88.1%
Latest Quarter
Free Cash Flow
$4.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CME Overvalued?
Given CME's positive net income, the trailing P/E ratio of 24.43x is the primary valuation metric, with a forward P/E of 22.10x, implying expected earnings growth. The stock trades at a premium to the broader market, but this is justified by its high margins and stable cash flows. Compared to industry averages, CME's P/E is above the sector median, reflecting its market leadership and growth prospects. Historically, the stock's P/E has ranged from 18.7x to 37.4x over the past five years, with the current level near the midpoint, suggesting fair valuation relative to its own history.
PE
24.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 19x~30x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are moderate, given CME's strong balance sheet with a debt-to-equity ratio of 0.13 and a current ratio of 92.97, indicating ample liquidity. However, the high payout ratio of 97.2% leaves little room for reinvestment, potentially limiting future growth. Revenue concentration in trading volumes makes earnings sensitive to market volatility, as evidenced by the 6-month price decline of -10.55% during a period of reduced activity. The company's reliance on continued growth to justify its premium valuation (forward P/E of 22.10x) poses a risk if volumes fail to meet expectations.
